Gilead's Harvoni wins Japanese nod
This article was originally published in Scrip
Executive Summary
Japanese authorities have approved Gilead's once-daily single pill, Harvoni (ledipasvir plus sofosbuvir), for hepatitis C genotype 1 patients. Also approved for genotype 1 patients in Japan are Merck & Co's Vanihep (vaniprevir) and Bristol-Myers Squibb's all-oral, interferon- and ribavirin-free two-pill regimen Daklinza (daclatasvir) and Sunvepra (asunaprevir), as well as Janssen Pharmaceutical's Sovriad (simeprevir). The news comes not long after Gilead's Sovalidi was granted a price well below that set in the US for genotype 2 patients. The Harvoni approval was backed by data from the Phase III clinical trial GS-US-337-0113 with 318 treatment-naïve and treatment-experienced Japanese patients with genotype 1 HCV infection randomized to ledipasvir plus sofosbuvir or ledipasvir plus sofosbuvir plus ribavirin.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.